Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Catalyst Pharm Inc
(NQ:
CPRX
)
19.87
-0.04 (-0.20%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Catalyst Pharm Inc
< Previous
1
2
3
4
5
6
7
8
9
Next >
ETF Returns: Mid-Cap Winners And Losers
June 28, 2023
We performed a screening of mid-cap ETFs - defined as having Assets Under Management (AUM) between $2 billion and $10 billion - to determine what funds had the largest positive and negative returns on...
Via
Benzinga
The Latest Analyst Ratings for Catalyst Pharmaceuticals
June 21, 2023
Via
Benzinga
Truist Securities Maintains Buy Rating for Catalyst Pharmaceuticals: Here's What You Need To Know
June 21, 2023
Via
Benzinga
Catalyst Pharmaceuticals to License North American Rights to Vamorolone for Duchenne Muscular Dystrophy from Santhera Pharmaceuticals
June 20, 2023
From
Catalyst Pharmaceuticals, Inc.
Via
GlobeNewswire
Catalyst Pharmaceuticals: Q1 Earnings Insights
May 10, 2023
Via
Benzinga
Catalyst Pharmaceuticals Inc. (NASDAQ: CPRX) is a Stock Spotlight on 4/11
April 11, 2023
Via
Investor Brand Network
1 Growth Stock to Buy Before the Next Bull Market
April 04, 2023
The stock is on a roll, and the company just made a major new purchase.
Via
The Motley Fool
Analyst Expectations for Catalyst Pharmaceuticals's Future
March 20, 2023
Via
Benzinga
The 7 Best Stocks Under $15 to Buy in June 2023
June 01, 2023
While you generally get what you pay for, these best stocks under $15 for June provide compelling opportunities at discount.
Via
InvestorPlace
Catalyst Pharmaceuticals Reports Positive Momentum in Second Quarter 2023
June 01, 2023
From
Catalyst Pharmaceuticals, Inc.
Via
GlobeNewswire
Catalyst Pharmaceuticals Appoints Tamar Thompson to its Board of Directors
May 30, 2023
From
Catalyst Pharmaceuticals, Inc.
Via
GlobeNewswire
Down 19% in 1 Day, Is Catalyst Pharmaceuticals a Smart Contrarian Buy?
May 22, 2023
When evaluating investments, it helps to keep quarterly performance in context.
Via
The Motley Fool
4 Analysts Have This to Say About Catalyst Pharmaceuticals
March 20, 2023
Via
Benzinga
Catalyst Pharmaceuticals Earnings Perspective: Return On Capital Employed
March 16, 2023
Via
Benzinga
Earnings Outlook For Catalyst Pharmaceuticals
March 14, 2023
Via
Benzinga
Ultragenyx Pharm Stock Clears Technical Benchmark, Hitting 80-Plus RS Rating
May 15, 2023
Ultragenyx Pharm shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 77 to 81.
Via
Investor's Business Daily
Market Rally Diverges; Google Surges On AI News, Inflation Cools, But Breadth Weak: Weekly Review
May 12, 2023
The Nasdaq hit a new 2023 high, but not the S&P 500 or Dow Jones.
Via
Investor's Business Daily
IBD 50 Leader And No. 1 Biotech Catalyst Puts Up 128% Earnings Growth
May 11, 2023
Though Catalyst's unadjusted earnings missed forecasts, they grew by triple digits.
Via
Investor's Business Daily
Catalyst Pharmaceuticals Reports Record First Quarter 2023 Results, Achieving 98% Total Revenue Growth Year-over-Year
May 10, 2023
From
Catalyst Pharmaceuticals, Inc.
Via
GlobeNewswire
Why Groupon Shares Are Trading Lower By 22%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
May 11, 2023
Gainers Sunshine Biopharma, Inc. (NASDAQ: SBFM) gained 109.8% to $1.06 after reporting a rise in Q1 sales.
Via
Benzinga
Catalyst Pharmaceuticals Advances sNDA Submission Plans To Increase Indicated Maximum Dose For FIRDAPSE® From 80 mg Per Day To 100 mg Per Day
May 09, 2023
From
Catalyst Pharmaceuticals, Inc.
Via
GlobeNewswire
Catalyst Pharmaceuticals Announces Release of Inaugural ESG Report
May 01, 2023
From
Catalyst Pharmaceuticals, Inc.
Via
GlobeNewswire
Catalyst Pharmaceuticals to Report First Quarter 2023 Financial Results on May 10, 2023
April 24, 2023
The Company Will Host a Conference Call and Webcast on May 11, 2023, at 8:30 AM ET
From
Catalyst Pharmaceuticals, Inc.
Via
GlobeNewswire
Catalyst Pharmaceuticals Announces Third-Party Abstracts on FYCOMPA® (Perampanel) to be Presented at the Upcoming American Academy of Neurology 2023 Annual Meeting
April 20, 2023
From
Catalyst Pharmaceuticals, Inc.
Via
GlobeNewswire
7 A-Rated Stocks to Buy for April 2023
April 07, 2023
Now that the first quarter's in the bank, here are seven A-rated stocks to buy for April to keep your portfolio in top-notch shape.
Via
InvestorPlace
2 Top Growth Stocks That Can Withstand an Economic Downturn
April 05, 2023
These two drugmakers should march higher in 2023 and beyond.
Via
The Motley Fool
Why Catalyst Pharmaceuticals Shares Are Moving
March 16, 2023
Catalyst Pharmaceuticals Inc (NASDAQ: CPRX) shares are trading higher by 9.66% to $15.72 Thursday morning after the company reported better-than-expected fourth-quarter results.
Via
Benzinga
Catalyst Pharma The No. 1 Biotech, Just Crushed 2023 Guidance Estimates
March 15, 2023
The guidance includes Catalyst's newest, and second, product.
Via
Investor's Business Daily
Catalyst Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
March 15, 2023
From
Catalyst Pharmaceuticals, Inc.
Via
GlobeNewswire
Earnings Scheduled For March 15, 2023
March 15, 2023
Companies Reporting Before The Bell • Sportradar Gr (NASDAQ:SRAD) is estimated to report quarterly earnings at $0.04 per share on revenue of $208.09 million.
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.